EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A novel prognostic model of de novo metastatic hormone-sensitive prostate cancer to optimize treatment intensity

Hiroshi Fujiwara, Masashi Kubota, Yu Hidaka, Kaoru Ito, Takashi Kawahara, Ryoma Kurahashi, Yuto Hattori, Yusuke Shiraishi, Yusuke Hama, Noriyuki Makita, Yu Tashiro, Shotaro Hatano und 15 weitere

International Journal of Clinical Oncology · 2024

DOI: 10.1007/s10147-024-02577-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2024. Verfasst von Hiroshi Fujiwara und 26 weiteren Autor:innen. Beteiligte Einrichtung: Shizuoka City Shizuoka Hospital, Shizuoka, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Androgen Antagonists. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nagoya University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The treatment and prognosis of de novo metastatic hormone-sensitive prostate cancer (mHSPC) vary. We established and validated a novel prognostic model for predicting cancer-specific survival (CSS) in patients with mHSPC using retrospective data from a contemporary cohort.

Methods

1092 Japanese patients diagnosed with de novo mHSPC between 2014 and 2020 were registered. The patients treated with androgen deprivation therapy and first-generation anti-androgens (ADT/CAB) were assigned to the Discovery ( N = 467) or Validation ( N = 328) cohorts. Those treated with ADT and androgen-receptor signaling inhibitors (ARSIs) were assigned to the ARSI cohort ( N = 81).

Results

Using the Discovery cohort, independent prognostic factors of CSS, the extent of disease score ≥ 2 or the presence of liver metastasis; lactate dehydrogenase levels > 250U/L; a primary Gleason pattern of 5, and serum albumin levels ≤ 3.7 g/dl, were identified. The prognostic model incorporating these factors showed high predictability and reproducibility in the Validation cohort. The 5-year CSS of the low-risk group was 86% and that of the high-risk group was 22%. Approximately 26.4%, 62.7%, and 10.9% of the patients in the Validation cohort defined as high-risk by the LATITUDE criteria were further grouped into high-, intermediate-, and low-risk groups by the new model with significant differences in CSS. In the ARSIs cohort, high-risk group had a significantly shorter time to castration resistance than the intermediate-risk group.

Conclusions

The novel model based on prognostic factors can predict patient outcomes with high accuracy and reproducibility. The model may be used to optimize the treatment intensity of de novo mHSPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsAndrogen AntagonistsHumansMaleAgedPrognosisRetrospective StudiesMiddle AgedAged, 80 and overJapanAndrogen Receptor Antagonists

Stichwörter der Autor:innen

Cancer-specific survivalPrognostic modelProstate cancermHSPC

Substanzen

Androgen AntagonistsAndrogen Receptor Antagonists

Autor:innen und Institutionen

  • Shizuoka City Shizuoka Hospital, Shizuoka, Japan.
  • Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Department of Urology, Miyazaki University Graduate School of Medicine, Miyazaki, Japan.
  • Department of Urology, Tsukuba University Graduate School of Medicine, Tsukuba, Japan.
  • Department of Urology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

Förderung

  • Nagoya University

Zitieren

APA

Fujiwara, H., Kubota, M., Hidaka, Y., Ito, K., Kawahara, T., Kurahashi, R., Hattori, Y., Shiraishi, Y., Hama, Y., Makita, N., Tashiro, Y., Hatano, S., Ikeuchi, R., Nakashima, M., Utsunomiya, N., Takashima, Y., Somiya, S., Nagahama, K., Fujimoto, T., …, & Akamatsu, S. (2024). A novel prognostic model of de novo metastatic hormone-sensitive prostate cancer to optimize treatment intensity. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02577-1

Vancouver

Fujiwara H, Kubota M, Hidaka Y, Ito K, Kawahara T, Kurahashi R, et al. A novel prognostic model of de novo metastatic hormone-sensitive prostate cancer to optimize treatment intensity. International Journal of Clinical Oncology. 2024. doi:10.1007/s10147-024-02577-1

BibTeX
@article{Fujiwara2024,
  author = {Fujiwara, Hiroshi and Kubota, Masashi and Hidaka, Yu and Ito, Kaoru and Kawahara, Takashi and Kurahashi, Ryoma and Hattori, Yuto and Shiraishi, Yusuke and Hama, Yusuke and Makita, Noriyuki and Tashiro, Yu and Hatano, Shotaro and Ikeuchi, Ryosuke and Nakashima, Masakazu and Utsunomiya, Noriaki and Takashima, Yasushi and Somiya, Shinya and Nagahama, Kanji and Fujimoto, Takeru and Shimizu, Kosuke and Imai, Kazuto and Takahashi, Takehiro and Sumiyoshi, Takayuki and Goto, Takayuki and Morita, Satoshi and Kobayashi, Takashi and Akamatsu, Shusuke},
  title = {A novel prognostic model of de novo metastatic hormone-sensitive prostate cancer to optimize treatment intensity},
  journal = {International Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1007/s10147-024-02577-1}
}
Kostenlos starten →